NEW YORK ( TheStreet) -- Nektar Therapeutics (Nasdaq: NKTR) hit a new 52-week low Monday as it is currently trading at $4.79, below its previous 52-week low of $4.81 with 32,185 shares traded as of 9:51 a.m. ET. Average volume has been 1.3 million shares over the past 30 days. Nektar has a market cap of $569.2 million and is part of the health care sector and drugs industry. Shares are down 62.3% year to date as of the close of trading on Friday. Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms.
- Practice your NKTR trading strategies and win cash in our stock game.